NCT05095519CompletedPhase 2
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
Hepatocellular Carcinoma Imaging Using PSMA PET/CT - a Prospective Pilot Trial
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
The purpose of the research is to evaluate the use of a PSMA PET/CT (Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography) scan in the diagnosis of HCC (hepatocellular carcinoma) and comparing it to standard scanning techniques with CT (Computed Tomography) or MRI (Magnetic Resonance Imaging).
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 21 Sept 2021
- Start date
- 8 Sept 2021
- Primary completion date
- 8 May 2026
- Lead sponsor
- Peter MacCallum Cancer Centre, Australia
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT05095519
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 30
- From 8 Sept 2021 to the primary completion date, 8 May 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Abdominal surgery or radiotherapy to the abdomen within \<4 weeks of registration. Patients must have recovered from any effects of any major surgery
- Other malignancies unless curatively treated with no evidence of disease within previous 3-years other than adequately treated non-melanoma skin cancer or melanoma in situ
- Participation in another clinical study with an investigational product or another systemic cancer therapy administered in the last 4 weeks
Other illness
- Uncontrolled intercurrent illness that is likely to impede participation and or compliance
- Any history of prostate cancer or elevated PSA level for male patients
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with requirements of the study
- Cirrhosis due to congenital hepatic fibrosis, vascular disorders (e.g. Budd-Chiari syndrome) or cardiac cirrhosis
Other
- Women who are pregnant or lactating
Who the study is looking for
- Male or female aged 18 years or older at screening
- Has provided written informed consent for participation in the study
- Must have risk factors for HCC e.g. cirrhosis, chronic hepatitis B infection with or without cirrhosis
- Patients with liver lesions ≥1 cm suspicious for HCC but with indeterminate features on CT and MRI meeting LI-RADS 3 or 4 criteria planned for biopsy, OR patients with liver lesions diagnostic of HCC based on CT or MRI meeting LI-RADS 5 criteria planned for surgical resection
- Patients must be willing and able to comply with the protocol and procedures for the duration of the study
- Patients must be available for follow-up
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St. Vincent's Hospital Coordinator of this site? Confirm its status | Fitzroy | Australia | Unknown status |
| Austin Health Coordinator of this site? Confirm its status | Heidelberg | Australia | Unknown status |
| Peter MacCallum Cancer Centre Coordinator of this site? Confirm its status | Melbourne | Australia | Unknown status |
| The Royal Melbourne Hospital Coordinator of this site? Confirm its status | Melbourne | Australia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.